Raymond F. Schinazi, Ph.D., D.Sc.
Professor and Director
Laboratory of Biochemical Pharmacology
|B.Sc., Hons Chemistry||University of Bath||Bath, England||1972|
|D.Sc. (Hon) Biotechnology||University of Bath||Bath, England||2006|
|Ph.D. Chemistry||University of Bath||Bath, England||1976|
- Post-doctoral Experience
- Postdoc, Pharmacology, Yale University, New Haven, CT, 1976-78
Postdoc, Virology/Immunology, Emory University, Atlanta, GA, 1978-81
- Honors and Awards
- Emory University, History Maker Award recipient, 2011
Metro Atlanta Chamber of Commerce, Bioscience Leadership Council Member, 2011-present
Emory University, Distinguished Lectureship, 2011-present
BioForward, Featured Speaker, 2011
Governing Trustee, Foundation for AIDS Research (amFAR), 2011-present
Board Member, International Centre for Missing and Exploited Children, 2012
Finance Committee Member, International Society for Nucleosides, Nucleotides, & Nucleic Acids (IS3NA), 2012-present
Inductee, Georgia Technology Hall of Fame, 2012
Advisory Committee Member, Schiff Center for Liver Diseases, University of Miami, 2012-present
Recipient, Intellectual Property Legends Award, Georgia State University, 2012
Charter Fellow , National Academy of Inventors, 2013
Board Member, Vaccine and Gene Therapy Institute of Florida (VGTI), 2013-present
Distinguished Medical Science Award, Friends of the National Library of Medicine (FNLM), 2013
SCRIP 100 Leaders, 2014
University of Bath (UK), Chancellor's Roll of Honor member, 2009; Harvard Medical School's Warren Alpert Foundation Prize Nominee, 2010; Society of Investigative Dermatology's Herman Beerman Lecturer, 2010; Editorial Board, 1984-2007: Antimicrob. Agents Chemother. 1990-present: Antiviral Res., Antiviral Chem. Chemother., US editor Intl. Antiviral News; 1995-present: Antiviral Therapy; 2001-present: AIDS Reviews. NSF (1987) and VA (1986-90) ad hoc grant reviewer. FDA ad hoc consultant, 1984 and 1987 (Anti-infective agents). NCI ad hoc advisor 1987-1989, NCI/NIAID Workshop on Issues for Implementation of a Natl. Anti-HIV Preclin. Drug Eval. Program. Nov. 1988 and May 1989 NIH Special Study Session July/Nov. 1989: SBIR Grants Program; Jan/March/July 1990: NIH Study Sessions AIDS and Related Research Review Group (AHR V1 and AHR V2); 90-94: AIDS and Related Research Review Group, Permanent Study Session, ARR-4 (Pharmacol.); 4/89-present VA Research Career Sc. Award. 1990-1993: VA AIDS Res. Ctr. Evaluation Committee; 12/93: Ad hoc NIH CFAR grants; 4/99: Ad hoc NIH grants; 1996: 12/96: Pediatric AIDS Clin. Trials Group Core Lab. NIH Study Session (Virology Cores); Presidential Commission on AIDS/Office of AIDS Research (Task Force on Therapeutics) and VA AIDS Task Force/Central Office; 4/97: Local Chairman, Intl. Soc. for Antiviral Res., Atlanta, GA; Dec. 95, 97 & 99: Founder and Co-Chair, Intl. Symp. Therap. Viral Hepatitis (HepDART); Dec. 98 & 00: Founder of ICDCD and HIV-DART meetings. 2000: Hepatitis B Foundation, Bruce Witte Annual Distinguished Award. 2000-present: Organizing Committee, International Workshop on HIV Drug Resistance Rx Strategies. 2001-present: American Liver Foundation Medical Advisory Committee (MAC); 2003: Georgia Biomedical Industry Growth Award; 8/05: NIH Study Session - Leadership for HIV/AIDS Clinical Trials Network; 2006: Distinguished Scientist Award from the Hepatitis B Foundation; 2006-present: VA R&D Committee Member (second tenure); Mar-2007: NIH Study Session Member - In Vitro Testing Resources for AIDS Therapeutics Development; Nov-2007: VA Research Career Scientist (RCS) Program Advisory Panel Mtg; 2008: Emory University Dean’s Distinguished Faculty Award; 2008: Endowed Chair. Frances Winship Walters Professor of Pediatrics; 2009-present: Editorial Board: HIV/AIDS - Research and Palliative Care; 2009: Emory University’s Office of Technology Transfer “Deal of the Year” and “Significant Event” Awardee.
- Research Interests
- The major research emphasis of the Laboratory of Biochemical Pharmacology is in two medically important areas. First, the group, composed of microbiologists, pharmacologists and virologists, focuses on the development of antiviral agents for the treatment of infections caused by human immunodeficiency viruses, and hepatitis viruses, herpesviruses, HBV, HCV, and Dengue virus.
Work involves molecular modeling, synthetic, biochemical, pharmacological, and molecular genetic approaches, including gene therapy and site-directed mutagenesis. The main objective is to develop preclinically, in-house compounds for the prevention and treatment of these important pathogens. Areas of particular interest include the phenotypic and genotypic characterization of drug-resistant virus variants and ways to overcome resistant viruses using combinations of antiviral drugs. Five compounds developed by this group have gone on to advanced clinical studies, and three have already been approved by the US FDA for the treatment of HIV-1 or HBV infections.
The second area of research is in the development of treatments for the protozoa Cryptosporidium parvum. Work involves animal models (SCID mice), cell culture methods, and molecular approaches (e.g., DNA library construction, sequencing) to identify targets unique to this organism.
Our multidisciplinary antiviral research is focused on discovering agents that could be used for the treatment HIV and hepatitis infections and on modalities aimed at preventing the development of drug-resistant viruses. Current research is in the fields of HIV-1, HIV-2, SIV, HBV, HCV, herpesviruses, Dengue virus and Cryptosporidium. The ongoing work is primarily funded from an NIH-sponsored Emory University Center for AIDS Research (CFAR), VA Merit and other awards, and several NIH grants, including two NIH Merit Awards.
- Representative Publications
- Hagan, L.M., Wolpe, P.R., and Schinazi, R.F.: Treatment as prevention and cure toward global hepatitis C virus eradication. Trends in Microbiology, Epub November 13, 2013. Epub ahead of print. PMID:24238778.
Ibrahim, M.A., Na, M., Oh, J., Schinazi, R.F., McBrayer, T.R., Whitaker, T., Doerksen, R.J., Newman, D.J., Zachos, L.G., and Hamman, M.T.: Significance of endangered and threatened plant natural products in the control of human disease. PNAS, 110(42):16832-16837, 2013. PMID:24082148.
Coats, S.J., Amblard, F., Ehteshami, M., Garnier-Amblard, E.C., Zhang, H., Zhou, L., Bondada, L., Chavre, S.N., Amiralaei, S., Boucle, S.R.L., Li, F., Lu, X., Shelton, J.R., Cho, J-H., Liu, P, Zhou, S., Mathew, J., and Schinazi, R.F.: Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res., Epub November 23, 2013. Epub ahead of print. PMID:24275341.
Gavegnano, C., Detorio, M., Montero, C., Bosque, A., Planelles, V., and Schinazi, R.F.: Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob. Agents Chemother., 58(4):1977-1986, 2014. PMID:24419350.
Schinazi, R.F., Halfon, P., Marcellin, P., and Asselah, T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int., 34 Suppl 1:69-78, 2014. PMID:24373081.